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The hormone hepcidin promotes iron sequestration by macrophages. A recent study by Kim et al. (2014)
implicates the orphan receptor ERRg (estrogen-related receptor g) in the regulation of hepcidin production
and suggests that targeting the ERRg-hepcidin axis may be beneficial during infection with the facultative
intracellular pathogen Salmonella.Macrophages play a central role in scav-
enging and recycling iron from senescent
red blood cells. This process is controlled
by the master regulatory hormone hep-
cidin, which is primarily synthesized in
the liver. During inflammation, the inter-
leukin-6 (IL-6)-inducible peptide hepcidin
promotes the degradation of its receptor,
the iron exporter ferroportin, resulting in
iron retention by macrophages, reduced
intestinal iron absorption, and hypoferre-
mia. While this iron-withholding response
is a central component of innate nutri-
tional immunity that restricts iron availabil-
ity to circulating microbes (Weiss and
Schett, 2013; Cassat and Skaar, 2013),
intracellular bacteria such as Salmonella
have been shown to benefit from the iron
retained within macrophages.
Adding to our understanding of iron
regulation during infection, a new study
by Kim et al. (2014) has implicated ERRg
(estrogen-related receptor g, also called
NR3B3), a nuclear hormone receptor
with no known activating ligand, in the
control of iron withholding. In this study,
Salmonella enterica sv. Typhimurium was
shown to induce hepcidin expression, hy-
poferremia, and ERRg expression inmice.
IL-6 knockout (KO) mice failed to exhibit
these responses and were observed to
have lower bacterial burdens, indicating
that ERRg acts downstream of IL-6 and
has a detrimental effect on host defense
against Salmonella. ERRg expression
was shown to result from transactivation
by the transcription factor STAT3. The
researchers further showed that overex-
pression of ERRg induces hepcidin pro-
duction and hypoferremia, and they were
able to identify anERRg response element
in the hepcidin promoter. ERRg did not
affect expression of NOS2 (inducible nitricoxide synthase), which can also alter iron
trafficking in macrophages by stimulating
iron export via ferroportin (Nairz et al.,
2013). A reverse agonist designated
GSK5182, which binds the ERRg receptor
and decreases its activity, was able to
ameliorate Salmonella-induced hepcidin
expression, hypoferremia, and iron accu-
mulation in the liver and spleen, along
with a reduction in bacterial burden,
macrophage iron content, and proinflam-
matory cytokine production. The authors
attributed the detrimental effects of hep-
cidin to increased iron availability in the
macrophages where Salmonella resides
(Figure 1). They suggested that ERRg
and hepcidin might be therapeutically tar-
geted to treat infections with intracellular
pathogens.
This study represents a significant
advance in our understanding of the reg-
ulatory linkage between innate immune
responses and iron homeostasis. Previ-
ous work by the same group has shown
that ERRg controls hepatic glucose pro-
duction in response to glucagon (Kim
et al., 2012), and it will be interesting to
see whether ERRg can account for the
observed association between IL-6 and
hyperglycemia in septic patients.
In considering the pharmacological
targeting of this pathway to treat infec-
tion with intracellular pathogens, a few
caveats are in order. First, observations
regarding the effects of hepcidin during
Salmonella infection have been somewhat
conflicting. Kim et al. (2014) found that
antagonism of hepcidin by the inhibition
of ERRg signaling is beneficial during sys-
temic Salmonella infection. This is consis-
tent with earlier observations showing
that hepcidin antagonism can ameliorate
Salmonella-induced inflammation (WangCell Host & Microbeet al., 2009) and that HFE mice, which
have deficient hepcidin expression, are
able to restrict Salmonella replication
(Nairz et al., 2009). However, in contrast,
hepcidin-deficient mice on a different
genetic background are reportedly more
susceptible to Salmonella challenge, and
hepcidin administration can enhance the
survival these mice during Salmonella
infection (Yuki et al., 2013). Differences
in inoculum size, mouse strain, route of
infection, iron distribution in tissues, and
effects of partial versus complete ERRg/
hepcidin inhibition are among the vari-
ables that should be further explored to
explain these discrepant findings.
Second, in addition to its regulation of
ferroportin, hepcidin can modulate host
inflammatory responses (Pagani et al.,
2011). Intracellular iron levels per se are
immunomodulatory, and the disruption
of iron homeostasis affects proinflamma-
tory cytokine production, either directly
via regulation of interferon gamma
(IFN-g) activity or by modulating the pro-
duction of nitric oxide or reactive oxygen
species, which in turn affect redox-sensi-
tive signaling pathways (Nairz et al., 2013;
Pagani et al., 2011; Weiss and Schett,
2013). In view of the relatively modest
effects of GSK5182 on bacterial burden,
particularly in the spleen, it is conceivable
that the survival benefit observed by Kim
et al. (2014) following GSK5182 treatment
might be attributable in part to reduced
immunopathology rather than to anti-
microbial effects resulting from lessened
iron availability. Previous studies have
suggested that hepcidin antagonists
can ameliorate inflammation in Salmo-
nella enterocolitis (Wang et al., 2009),
and effects of iron homeostasis on T
lymphocyte and macrophage polarization15, May 14, 2014 ª2014 Elsevier Inc. 515
Figure 1. Estrogen-RelatedReceptor gRegulates Host Iron Trafficking by InducingHepcidin
Formation in the Liver
ERRg transcription is stimulated by interleukin-6 (IL-6) and the transcription factor STAT3. Hepcidin is
released into the circulation and binds to the iron export protein ferroportin 1 (FP1), resulting in FP1 degra-
dation and macrophage iron retention. This results in systemic hypoferremia but increases access of the
intracellular pathogenSalmonella to iron. The increase inmacrophage iron levels also inhibits interferon-g-
dependent antibacterial immune responses. ERRg inhibition by the reverse agonist GSK5182 counteracts
the effects of hepcidin on intramacrophage iron availability and antimicrobial immune effector pathways
but may increase the availability of iron to extracellular pathogens.
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Previewshave been described (Weiss and Schett,
2013). Immunomodulatory actions of
ERRg and hepcidin will have to be care-
fully considered when targeting these
proteins during infection, as such actions
may be either protective or detrimental
depending on the nature and primary
localization of the microbe and time
course of the specific host-pathogen
interaction (Cassat and Skaar, 2013; Dra-
kesmith and Prentice, 2012).
Finally, it must be remembered that
the changes in iron compartmentalization
mediated by hepcidin can restrict the
growth of pathogens at some tissue sites516 Cell Host & Microbe 15, May 14, 2014 ª2and in the circulation while having the
opposite effect on intracellular pathogens.
Accordingly, hepcidin plays a protective
antimicrobial role in host resistance to
Vibrio vulnificus, Yersinia, and Plasmo-
dium spp., despite promoting the growth
of Salmonella, Leishmania, andmycobac-
teria in macrophages (Cassat and Skaar,
2013; Drakesmith and Prentice, 2012;
Nairz et al., 2013). Therapeutic targeting
of the ERRg-hepcidin-ferroportin axis
during infection will therefore require a
detailed knowledge of the cellular locali-
zation of the specific pathogen involved.
Coinfection with malaria and Salmonella014 Elsevier Inc.or tuberculosis, not an infrequent sce-
nario in Africa, would pose a therapeu-
tic dilemma from an iron standpoint.
Depriving one pathogen only to benefit
another would be, one might say, ironic.
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